Scrip's Stock Tracker: March 2010
This article was originally published in Scrip
Executive Summary
Passage of the US healthcare reform in the House of Representatives on 21 March cleared one of the US stock market's biggest uncertainties out of the way, to the general benefit of drug stocks and traders. Gainers on the day included: Bristol-Myers Squibb, rising by 1.8%; Pfizer, up by 1.4%; and Merck & Co, which gained 0.6%.
You may also be interested in...
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Swiss-EU Standoff Set To End? Medtechs Eye MRA Action
Negotiations aimed at renewing the close trading relationship and barrier-free mutual market access between Switzerland and the EU got underway on 19 March. Swiss medtech companies welcomed the move, stressing the need for the defunct mutual recognition agreement to be updated.
A Healthtech Global Software Business With A Silicon Valley Look
Royal Philips’ head of Enterprise Informatics Shez Partovi explains the rationale behind the 2023 decision to set up a vertical business for digital, AI and software applications, to operate alongside imaging, monitoring and interventional therapy.